EP0434707A1 - Derives de 6-oxo-9-fluor-prostaglandine, leur procede de production et leur utilisation pharmaceutique - Google Patents
Derives de 6-oxo-9-fluor-prostaglandine, leur procede de production et leur utilisation pharmaceutiqueInfo
- Publication number
- EP0434707A1 EP0434707A1 EP19890909709 EP89909709A EP0434707A1 EP 0434707 A1 EP0434707 A1 EP 0434707A1 EP 19890909709 EP19890909709 EP 19890909709 EP 89909709 A EP89909709 A EP 89909709A EP 0434707 A1 EP0434707 A1 EP 0434707A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- free
- formula
- μmol
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 12
- 230000008569 process Effects 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- -1 hydroxymethylene group Chemical group 0.000 claims abstract description 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- 239000002502 liposome Substances 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 4
- 125000004429 atom Chemical group 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims description 2
- 239000012025 fluorinating agent Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 239000012230 colorless oil Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000002253 acid Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 238000010626 work up procedure Methods 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 150000004702 methyl esters Chemical class 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 239000002585 base Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003810 Jones reagent Substances 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000002222 fluorine compounds Chemical class 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- QYKVOIFUTUJFKA-CRMZQXOWSA-N methyl 7-[(1S,2S)-2-(4-methylnona-1,6-diynyl)cyclopentyl]-2-(oxan-2-yloxy)heptanoate Chemical compound COC(C(CCCCC[C@H]1CCC[C@@H]1C#CCC(CC#CCC)C)OC1OCCCC1)=O QYKVOIFUTUJFKA-CRMZQXOWSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000012027 Collins reagent Substances 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- JZULKTSSLJNBQJ-UHFFFAOYSA-N chromium;sulfuric acid Chemical compound [Cr].OS(O)(=O)=O JZULKTSSLJNBQJ-UHFFFAOYSA-N 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940124569 cytoprotecting agent Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- WHFKIZXBVFEJGA-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 WHFKIZXBVFEJGA-UHFFFAOYSA-L 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N ortho-diethylbenzene Natural products CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
Definitions
- the invention relates to new 6-oxo-9-fluoroprostaglandin derivatives, processes for their preparation and their use as medicaments.
- the compounds of this invention are useful in the therapy of diseases of the cardiovascular system, the stomach, the pancreas, the liver and the kidney. They have a hypotensive and bronchodilatory effect. They are suitable for inhibiting platelet activation. Consequently, the new 6-oxo-9-fluoroprostaglandin derivatives of the formula I are valuable active pharmaceutical ingredients.
- the invention relates to 6-oxo-9-fluoroprostaglandin derivatives of the formula I.
- R 1 represents the radical COOR 2 or CONHSO 2 R 2 with R 2 meaning a C 5 -C 6 cycloalkyl or a C 6 -C 12 aryl group or a 5- or 6-membered heterocyclic radical or, if R 1 is COOR 2 , R 2 is a
- W is a free or functionally modified hydroxymethylene group or a free or functionally modified OH group, the OH group
- D is a straight-chain or branched-chain alkylene group with 1-5 C atoms or a direct bond
- E is a -C ⁇ C group, a C 2 -C 4 alkenylene group or a group,
- R 3 represents a hydrogen atom, a C 1 -C 10 alkenyl, C 3 -C 10 cycloalkyl or an optionally substituted C 6 -C 12 aryl group or a 5- or 6-membered heterocyclic group,
- R 4 represents a hydrogen atom, a methyl group or a free or functionally modified hydroxy group and, if R 2 has the meaning of a hydrogen atom, the salts thereof with physiologically compatible bases, the ⁇ -, ⁇ - or ⁇ -cyclodextrin clathrates of the compounds of the formula I and also compounds of formula I encapsulated with liposomes
- alkyl groups R 2 straight or branched chain alkyl groups with 1-10 C atoms are meant, such as methyl, ethyl, propyl, isopropyl, butyl,
- alkyl groups R 2 can optionally be substituted one to more times by
- Halogen atoms hydroxyl groups, C 1 -C 4 alkoxy groups, optionally substituted
- alkyl groups are those which are monosubstituted. Examples of substituents are fluorine, chlorine or bromine atoms, phenyl, dimethylamino, diethylamino, methoxy, ethoxy.
- Preferred alkyl groups R 2 are those with 1-4 C atoms, such as methyl,
- Suitable aryl groups R 2 are both substituted and unsubstituted aryl groups, such as phenyl, ⁇ - or ⁇ -naphthyl and diphenyl. These groups can be substituted by 1-3 halogen atoms, a phenyl group, 1-3 alkyl groups each with 1-4 C atoms, a chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, hydroxyl or alkoxy group with 1-4 C atoms his.
- the substituents in the 3- and 4-position on the phenyl ring are preferred, for example by fluorine, chlorine, alkoxy or trifluoromethyl or in the 4-position by hydroxy.
- the cycloalkyl groups R 2 can contain 3-10, preferably 5 and 6, carbon atoms in the ring.
- the rings can be substituted by alkyl groups with 1-4 carbon atoms. Examples include cyclopentyl, cyclohexyl, methylcyclohexyl and adamantyl.
- Suitable heterocyclic groups R 2 are 5- and 6-membered heterocycles, which preferably contain a heteroatom, preferably nitrogen, oxygen or sulfur.
- hydroxyl groups R 4 , R 5 and in W can be functionally modified, for example by etherification or esterification, it being possible for the free or modified hydroxyl groups in W and R 5 to be ⁇ - or ⁇ -permanent and free hydroxyl groups are preferred.
- Suitable ethers and acyl radicals are the radicals known to the person skilled in the art. Easily cleavable ether radicals, such as, for example, the tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, methoxyethyl, tert-butyldimethylsilyl, tert-butyl-diphenylsilyl, the ⁇ yl-dimethylsilyl and ⁇ -tribenzylsilyl radical, are preferred.
- Acyl radicals which may be mentioned are, for example, acetyl, propionyl, butyryl and benzoyl.
- Suitable alkyl groups R 3 are straight-chain and branched-chain, saturated and unsaturated alkyl radicals, preferably saturated, with 1-10, in particular 1-7, carbon atoms, which may optionally be substituted by optionally substituted aryl. Examples include methyl, ethyl, propyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, butenyl, isobutenyl, propenyl, pentyl, hexenyl, benzyl and p-chlorobenzyl.
- the cycloalkyl group R 3 can contain 3-10, preferably 3-6 carbon atoms in the ring.
- the rings can be substituted by alkyl groups with 1-4 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclohexyl and adamantyl.
- substituted or unsubstituted aryl groups R 3 are phenyl, 1-naphthyl and 2-naphthyl, diphenyl, each of which is represented by 1-3 halogen atoms, a phenyl group, 1-3 alkyl groups each having 1-4 carbon atoms
- Chloromethyl, fluoromethyl, trifluoromethyl, carboxyl, C 1 -C 4 alkoxy or hydroxy group can be substituted.
- the substitution in the 3- and 4-position on the phenyl ring is preferred, for example by fluorine, chlorine, C 1 -C 4 -alkoxy or trifluoromethyl or in the 4-position by hydroxy.
- Suitable heterocyclic groups R 3 are 5- and 6-membered heterocycles which contain at least 1 heteroatom, preferably nitrogen, oxygen or sulfur. Examples include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl and 4-pyridyl.
- Suitable alkylene groups D are straight-chain or branched-chain, saturated and unsaturated alkylene radicals, preferably saturated ones with 1-10, in particular 1-5, carbon atoms, which can optionally be substituted by fluorine atoms. Examples include methylene, fluoromethylene, ethylene, 1, 2-propylene, ethylethylene, trimethylene, tetramethylene, pentamethylene, 1-methyltetramethylene and 1-methyl-trimethylene.
- R 2 H
- the invention further relates to a process for the preparation of the compounds of formula I, which is characterized in that a compound of formula II
- X is a or group
- R 5 is a hydroxyl group and R 1 , R 3 , R 4 , A, W, D and E have the meanings given above and free OH groups in R 4 , R 5 and W are protected with diethylaminosulfur trifluoride [M. Sharma, Tetrahedron Lett. 57j (197%); WJ
- the reaction of the compounds of general formula II to the compounds of general formula I is carried out with diethylaminosulfur trifluoride at -80 ° C to +40 ° C, preferably at -70 ° C to +20 ° C.
- diethylaminosulfur trifluoride As a solvent are dichloromethane, 1.1.2-trifluorotrichloroethane, pyridine, toluene, benzene, ethylene chloride and others, but preferably toluene and methylene chloride.
- the release of the functionally modified hydroxy groups R 4 , R 5 and in W and the oxidation of the released hydroxy group R 5 to the ketone is carried out according to the methods known to the person skilled in the art (DE 370853%).
- the hydroxyl group in X is oxidized by the processes known to the person skilled in the art. Chromium sulfuric acid, for example, comes as the oxidizing agent
- reaction is carried out with Jones reagent at -40 ° C to 0 ° C, preferably at -30 ° C to -10 ° C, using the other oxidizing agents, preferably at -10 ° C to +25 ° C.
- Suitable solvents are methylene chloride, chloroform, ethylene chloride, acetone, pyridine, among others, but preferably methylene chloride and acetone.
- ether protecting groups in an aqueous solution of an organic acid, e.g. Acetic acid, propionic acid, citric acid u. a. or in an aqueous solution of an inorganic acid, e.g. Hydrochloric acid, or in the case of tetrahydropyranyl ethers using pyridinium p-toluenesulfonate, preferably in alcohols as a solvent or using anhydrous magnesium bromide, preferably in diethyl ether as a solvent.
- an organic acid e.g. Acetic acid, propionic acid, citric acid u. a.
- an inorganic acid e.g. Hydrochloric acid
- tetrahydropyranyl ethers using pyridinium p-toluenesulfonate preferably in alcohols as a solvent or using anhydrous magnesium bromide, preferably in diethyl ether as a solvent.
- a water-miscible inert solvent is advantageously added when using aqueous-acidic reaction conditions.
- Alcohols such as methanol and ethanol, ethers such as dimethoxyethane, dioxane and tetrahydrofuran, with tetrahydrofuran preferably being used.
- the silyether protecting groups are cleaved off, for example, using tetrabutylamm ⁇ nium fluoride. Tetrahydrofurao diethyl ether, dioxane, methylene chloride etc. are suitable as solvents.
- the cleavage is preferably carried out at temperatures between 20 ° C and 80 ° C.
- the saponification of the acyl groups and prostaglandin esters is carried out according to the methods known to the person skilled in the art, such as, for example, with basic catalysts such as, for example, with alkali metal or alkaline earth metal carbonates or hydroxides in an alcohol or in the aqueous solution of an alcohol.
- Aliphatic alcohols such as, for example, methanol, ethanol, butanol, etc. are suitable as alcohols, but preferably methanol.
- Potassium and sodium salts may be mentioned as alkali carbonates and hydroxides.
- the potassium salts are preferred.
- Suitable alkaline earth carbonates and hydroxides are, for example, calcium carbonate, calcium hydroxide and tree carbonate.
- the reaction is generally carried out at -10 ° C to +70 ° C, but preferably at +25 ° C.
- ester group CO 2 R 2 for R 1 in which R 2 represents an alkyl group with 1-10 C atoms, takes place according to the methods known to the person skilled in the art.
- the 1-carboxy compounds (R 2 - H) are reacted, for example, with diazo hydrocarbons in a manner known per se.
- the esterification with diazo hydrocarbons takes place, for example, by dissolving the diazo hydrocarbon in an inert solvent, preferably in diethyl ether, with the
- Diazole alkanes are either known or can be prepared by known methods [Org. Reactions Vol. 8, pp. 389-394
- ester group CO 2 R 2 for R 1 in which R 2 represents a substituted or unsubstituted aryl group, takes place according to the methods known to the person skilled in the art.
- the 1-carboxy compounds are reacted with the corresponding arylhydroxy compounds with dicyclohe ⁇ ylcarbodiimide in the presence of a suitable base such as pyridine, dimethylaminopyridine, triethylamine, in an inert solvent such as methylene chloride, ethylene chloride, chloroform, ethyl acetate, tetrahydrofuran, but preferably chloroform.
- a suitable base such as pyridine, dimethylaminopyridine, triethylamine
- an inert solvent such as methylene chloride, ethylene chloride, chloroform, ethyl acetate, tetrahydrofuran, but preferably chloroform.
- the reaction is carried out at temperatures between -30 ° C and +50 ° C,
- the prostaglandin derivatives of the formula I with R 1 in the meaning of a hydrogen atom can be mixed with suitable amounts of the corresponding inorganic bases be converted into salts with neutralization.
- suitable amounts of the corresponding prostaglandic acids are dissolved in water which contains stoichiometric amounts of the base, the solid inorganic salt is obtained after the water has been evaporated off or after a water-miscible solvent, for example alcohol or acetone, has been added.
- the amine salts are prepared in a conventional manner.
- the prostaglandic acid is dissolved in a suitable solvent, e.g. Ethanol, acetone, diethyl ether or benzene and add 1 to 5 equivalents of the respective amine to this solution.
- a suitable solvent e.g. Ethanol, acetone, diethyl ether or benzene
- the salt is usually obtained in solid form or is isolated in a conventional manner after evaporation of the solvent.
- the functional modification of the free hydroxyl groups takes place according to the methods known to the person skilled in the art.
- To introduce the ether protecting groups for example, with dihydropyran or methyl vinyl ether in methylene chloride or chloroform using catalytic amounts of an acidic condensing agent such as e.g. p-toluenesulfonic acid.
- the respective enol ether is added in excess, preferably in 1.5 to 10 times the theoretical amount.
- the reaction normally takes place at -10 ° C to +30 ° C and is complete after 2-30 minutes.
- the acyl protective groups are introduced by reacting a compound of the formula I in a manner known per se with a carboxylic acid derivative, e.g. Acid chloride, acid anhydride, etc., implemented.
- a carboxylic acid derivative e.g. Acid chloride, acid anhydride, etc.
- the new 6-oxo-9-fluor prostaglandin derivatives have the properties typical of this class of compounds, such as lowering peripheral arterial, coronary and pulmonary vascular resistance, lowering pulmonary blood pressure.
- the new 5-oxo-9-fluor-prostaglandin derivatives are principally suitable for the treatment of stroke, the prophylaxis and therapy of coronary heart diseases, for Examples of coronary thrombosis, for the treatment of myocardial infarction, peripheral arterial diseases, for prophylaxis and therapy for other thromboembolic diseases and for arteriosclerosis, for chemical attacks of the CNS system and other circulatory disorders of the brain, for the treatment of hypertension and for the treatment of diseases associated with Increase in pulmonary vascular resistance such as pulmonary hypertension and for the treatment of shock and asthma. They can also be used to inhibit labor pains and to treat pregnancy toxicosis.
- the new 6-oxo-9-fluoroprostaglandin derivatives can also be used to improve organ function after transplantation, for example in kidney transplantation, to prevent rejection reactions, instead of heparin or as an adjuvant in dialysis or hemofiltration and in the preservation of preserved blood plasma, for example preserved blood platelets.
- the new 6-oxo-9-fluor prostaglandin derivatives have an antimetastatic effect and antiproliferative properties.
- 6-oxo-9-fluoroprostaglandin derivatives of this invention can also be used in combination, e.g. with ß-blockers, diuretics, phosphodiesterase inhibitors, Ca antagonists, nothing teroidal anti-inflammatories, leukotriene synthetase inhibitors, leukotriene antagonists, thrombo-kinesan synthetase inhibitors or thrombo-kan antagonists.
- the dose of the compounds is 1-1000 ⁇ g / kg / day when administered to the human patient.
- the unit dose for the pharmaceutically acceptable carrier is 10 ⁇ g to 100 ⁇ g.
- Sterile, injectable aqueous or oily solutions are used for parenteral administration.
- Tablets, coated tablets or capsules, for example, are suitable for oral administration.
- the invention thus also relates to medicaments based on the compounds of the formula I and customary auxiliaries and excipients, including cyclodextrin lactate and encapsulation with liposomes.
- the active compounds according to the invention are to be used in conjunction with the auxiliaries known and customary in galenics, for example for the production of hypotensive agents, platelet aggregation inhibitors or cytoprotectants.
- auxiliaries known and customary in galenics, for example for the production of hypotensive agents, platelet aggregation inhibitors or cytoprotectants.
- Example 1a 45 mg (81.7 ⁇ mol) of the compound shown in Example 1a were mixed with 2 ml of a glacial acetic acid: water: tetrahydrofuran (65:35: 10) mixture and the mixture was stirred at 23 ° C. for 15 hours. The mixture was concentrated in a water jet vacuum and residual acetic acid was removed azeotropically by repeated addition of toluene. The crude oil obtained was purified by chromatography on an analytical thin-layer plate. A mixture of dichloromethane and methanol was used as the eluent, and a mixture of chloroform and isopropanol as the eluent. 23 mg (60 ⁇ mol, 73%) of the title compound were isolated as a colorless oil.
- Example 1b 48 mg (85 ⁇ mol) of the compound shown in Example 1b was dissolved in 1.4 ml of methanol, mixed with 0.5 ml of an aqueous potassium hydroxide solution and stirred at 23 ° C. for 2.5 hours.
- the methanol was removed in a water jet vacuum, diluted with a little water, acidified with saturated citric acid and extracted several times with a total of 15 ml of chloroform.
- the organic phase was washed with H 2 O, dried over magnesium sulfate and isolated after filtration and removal of the solvent in a water jet vacuum 45 mg (82 ⁇ mol, 96%) of the title compound as a colorless oil.
- Example 1c 280 mg (498 ⁇ mol) of the compound shown in Example 1c was dissolved in 8.5 ml of anhydrous toluene, 395 ⁇ l of anhydrous pyridine were added, the mixture was cooled to -70 ° C. under an atmosphere of dry argon and 297 ⁇ l of diethylaminosulfur trifluoride were added. The mixture was allowed to warm slowly to 20 ° C., mixed with a few drops of a saturated sodium bicarbonate solution, diluted with water and extracted several times with dichloromethane. After drying over magnesium sulfate, filtration and concentration in a water jet vacuum, the residue was purified by chromatography on about 30 ml of fine silica gel under pressure.
- the mixture was diluted with 100 ml of ethyl acetate, washed several times with water, dried over magnesium sulfate and, after filtration and removal of the solvent, 5.1 g of a yellow oil were isolated.
- the residue was placed on a silica gel column and eluted after a two-hour residence time with a mixture of dichloromethane / ace volume. 4.28 g (7.6 mmol, 81%) of the title compound were isolated as a colorless oil.
- Example 2a 48 mg (90 ⁇ mol) of the compound shown in Example 2a were reacted analogously to Example 1 and, after working up and chromatographic purification, 25 mg (65 ⁇ mol, 72%) of the title compound were isolated as a colorless oil.
- Example 2e 550 mg (811 ⁇ mol) of the compound shown in Example 2e were reacted analogously to Example 1b and, after workup and chromatographic purification, 330 mg (485 ⁇ mol, 60%) of the title compound were isolated as a colorless oil.
- Example 2j 1.32 g (1.99 mmol) of the compound shown in Example 2j was dissolved in a mixture of 16 ml of anhydrous methanol and 5 ml of anhydrous dichloromethane, cooled to -40 ° C. under an atmosphere of dry argon and a total of 455 was added in portions mg sodium borohydride. The mixture was left to react at -40 ° C. for 1 hour, mixed with 740 ⁇ l of glacial acetic acid and concentrated in a water jet vacuum.
- Example 2 11 mg (29 ⁇ mol) of the compound shown in Example 2 was esterified analogously to Example 3 and, after purification, 8.5 mg (21 ⁇ mol, 74%) of the title compound was isolated as a colorless oil.
- Example 5a 37 mg (66 ⁇ mol) of the compound shown in Example 5a were reacted analogously to Example 1 and, after workup and purification, 17 mg (43 ⁇ mol, 65%) of the title compound were isolated as a colorless oil.
- Example 5b 41 mg (73 ⁇ mol) of the fluorine compound shown in Example 5b is saponified in analogy to Example 1a and, after workup and purification, 37 mg (66 ⁇ mol, 90%) of the title compound are isolated as a colorless oil.
- Example 5c 243 mg (422 ⁇ mol) of the compounds shown in Example 5c were reacted analogously to Example 1b and, after working up and chromatographic separation, 45 mg (81 ⁇ mol, 19%) of the title compound A and 41 mg were isolated
- Example 6a 35 mg (62 ⁇ mol) of the compound shown in Example 6a was reacted analogously to Example 1 and, after workup and purification, 19 mg (48 ⁇ mol, 77%) of the title compound were isolated as a colorless oil.
- Example 6b 61 mg (108 ⁇ mol) of the compound shown in Example 6b were reacted analogously to Example 2a and, after workup and purification, 35 mg (62 ⁇ mol, 57%) of the title compound were isolated as a colorless oil.
- Example 6c 99 mg (152 ⁇ mol) of the compound shown in Example 6c were reacted analogously to Example 2b and, after workup and purification, 61 m (108 ⁇ mol. 71%) of the title compound were isolated as a colorless oil.
- Example 6d 105 mg (158 ⁇ mol) of the compound shown in Example 6d were reacted analogously to Example 1a and, after working up and purification, 99 mg (152 ⁇ mol, 96%) of the title compound were isolated as a colorless oil.
- IR film 3600-2500, 2960, 2920, 2860, 2230, 1730, 1710, 1445, 1130, 1080,
- Example 6e 107 mg (164 ⁇ mol) of the compound shown in Example 6e were reacted analogously to Example 1b and, after workup and purification, 61 mg (92 ⁇ mol, 56%) of the title compound were isolated as a colorless oil.
- Example 6f 150 mg (198 ⁇ mol) of the compound shown in Example 6f were reacted analogously to Example 2e and isolated after workup and purification
- Example 6g 142 mg (217 ⁇ mol) of the compound shown in Example 6g were reacted analogously to Example 2f and, after workup and purification, 155 mg (204 ⁇ mol, 94%) of the title compound were isolated as a colorless oil.
- Example 6i 468 mg (719 ⁇ mol) of the compound shown in Example 6i were reacted analogously to Example 2h and, after workup and purification, 425 mg (561 ⁇ mol, 78%) of the title compound were isolated as a colorless oil.
- Example 6j 550 mg (848 ⁇ mol) of the compound shown in Example 6j were reacted analogously to Example 2i and, after workup and purification, 473 mg (727 ⁇ mol, 86%) of the title compound were isolated as a colorless oil.
- Example 6j
- Example 5c 518 mg (900 ⁇ mol) of the compound shown in Example 5c was reacted analogously to Example 2j and, after workup and purification, 562 mg (866 ⁇ mol, 96%) of the title compound was isolated as a colorless oil.
- Example 5 6.5 mg (16.4 ⁇ mol) of the compound shown in Example 5 was reacted analogously to Example 3 and, after workup and purification, 4.8 mg (11.7 ⁇ mol, 717.) of the title compound was isolated as a colorless oil.
- Example 6 9 mg (22.7 ⁇ mol) of the compound shown in Example 6 was reacted analogously to Example 3 and, after workup and purification, 6.5 mg (15.9 ⁇ mol, 70%) of the title compound were isolated as a colorless oil.
Abstract
Des dérivés de 6-oxo-9-fluor-prostaglandine ont la formule (1), dans laquelle R1 représente les résidus COOR2 ou CONHSO2R2, où R2 est un groupe C5-C6-cycloalkyle ou C6-C12-aryle ou un résidu hétérocyclique pentagonal ou hexagonal, ou lorsque R1 est COOR2, R2 peut représenter un atome d'hydrogène ou un phénacyle libre ou substitué par 1-3 atomes d'halogène, A est un groupe CH=CH ou -C=C- à configuration en E, W est un groupe hydroxyméthylène libre ou fonctionnellement transformé ou un groupe (a) libre ou fonctionnellement transformé, alors que le groupe OH peut être situé en alpha ou en beta, D est un groupe alkylène à chaîne droite ou ramifiée ayant entre 1 et 5 atomes de de carbone ou est une liaison directe, E est un groupe -C=C-, un groupe C2-C4-alkényle, ou un groupe (b); R3 est atome d'hydrogène, un groupe C2-C4-alkenylène, un groupe C3-C10-cycloalkyle, un groupe C6-C12-aryle éventuellement substitué ou un groupe hétérocyclique pentagonal ou hexagonal, R4 est atome d'hydrogène, un groupe méthyle ou un groupe hydroxyle libre ou fonctionnellement transformé, et lorsque R2 représente un atome d'hydrogène, ses sels avec des bases physiologiquement compatibles, des clathrates de cyclodextrine alpha, beta ou gamma. L'invention concerne également les composés de formule (I) encapsulés dans des liposomes, leur procédé de production et leur utilisation pharmaceutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3831222 | 1988-09-09 | ||
DE19883831222 DE3831222A1 (de) | 1988-09-09 | 1988-09-09 | 6-oxo-9-fluor-prostaglandin-derivate verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0434707A1 true EP0434707A1 (fr) | 1991-07-03 |
Family
ID=6362926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19890909709 Withdrawn EP0434707A1 (fr) | 1988-09-09 | 1989-09-10 | Derives de 6-oxo-9-fluor-prostaglandine, leur procede de production et leur utilisation pharmaceutique |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0434707A1 (fr) |
DE (1) | DE3831222A1 (fr) |
WO (1) | WO1990002728A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666256A1 (fr) * | 1992-10-20 | 1995-08-09 | Taisho Pharmaceutical Co. Ltd | Derive de prostaglandine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3126924A1 (de) * | 1981-07-03 | 1983-01-20 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 9-fluor-prostaglandinderivate, verfahren zur herstellung und verwendung als arzneimittel |
DE3708537A1 (de) * | 1987-03-13 | 1988-09-22 | Schering Ag | 6-oxoprostaglandin-e-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
-
1988
- 1988-09-09 DE DE19883831222 patent/DE3831222A1/de not_active Withdrawn
-
1989
- 1989-09-10 EP EP19890909709 patent/EP0434707A1/fr not_active Withdrawn
- 1989-09-10 WO PCT/DE1989/000588 patent/WO1990002728A2/fr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9002728A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO1990002728A3 (fr) | 1990-07-26 |
WO1990002728A2 (fr) | 1990-03-22 |
DE3831222A1 (de) | 1990-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0051558B1 (fr) | Dérivés de la prostacycline, leur préparation et leur utilisation dans des médicaments | |
EP0563358B1 (fr) | Derives bicyclo [3.3.0]octanes 9-substitues, pouvant etre utilises comme antagonistes de txa2 | |
EP0099538A1 (fr) | Carbacyclines, procédé pour leur préparation et leur utilisation comme médicaments | |
EP0130142A1 (fr) | Dérivés de prostacycline, procédé pour leur préparation et leur utilisation comme médicament | |
EP0057660A2 (fr) | Dérivés de prostacycline, leurs préparations et applications comme médicaments | |
EP0284547B1 (fr) | Dérivés 6-oxo prostaglandine-E, leur préparation et médicaments les contenant | |
DE4225488A1 (de) | Neue Bicyclo[3.3.0]octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung | |
EP0434707A1 (fr) | Derives de 6-oxo-9-fluor-prostaglandine, leur procede de production et leur utilisation pharmaceutique | |
EP0434833B1 (fr) | Derives de 9-fluor-prostaglandine, leur procede de production et leur utilisation pharmaceutique | |
EP0051557B1 (fr) | Dérivés 5-cyano-prostacyclines, leur procédé de préparation et leur utilisation dans des médicaments | |
EP0153274B1 (fr) | Carbacyclines, procédé pour leur préparation et leur utilisation comme médicaments | |
EP0051597B1 (fr) | Nouveaux derives de prostacycline et leur preparation | |
DE3428266A1 (de) | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
DD209806A5 (de) | Verfahren zur herstellung von carbacyclinen | |
EP0098794B1 (fr) | Carbacyclines, procédé pour leur préparation et leur utilisation comme médicaments | |
EP0113311B1 (fr) | 5-Fluorocarbacyclines, procédé pour leur préparation et leur utilisation comme médicaments | |
EP0434832B1 (fr) | DERIVES DE D8- et de D9-PROSTAGLANDINE, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION PHARMACEUTIQUE | |
DE4037941A1 (de) | Cyclopentanetherderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
EP0155901B1 (fr) | Carbacyclines, procédé pour leur préparation et leur utilisation comme médicaments | |
WO1989000990A1 (fr) | Nouveaux derives de carbacycline substitues en 9, leur procede de fabrication et leur emploi a titre de medicaments | |
WO1987003283A1 (fr) | Nouvelles carbacyclines, leur procede de production et utilisation comme medicaments | |
DE4010355A1 (de) | Bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
EP0139731A1 (fr) | 5-ethinyl-prostacycline, son procede de fabrication et son utilisation pharmaceutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19910122 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19930401 |